Login to Your Account

Drug Misses in Acute Flares

All About Gout: Arcalyst Meets Phase III Prophylaxis Endpoint

By Jennifer Boggs

Thursday, June 10, 2010
It was a good news/bad news day for Regeneron Pharmaceuticals Inc., which reported Phase III data showing that IL-1 blocker Arcalyst (rilonacept) was successful in preventing gout attacks but failed to provide pain relief in the acute gout treatment setting. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription